Solid forms of an antiviral compound
First Claim
Patent Images
1. Crystalline 5-(3,3-dimethylbutyn-1-yl)-3-[(cis-4-hydroxy-4-{[(3S)-tetrahydrofuran-3-yloxy]methyl}cyclohexyl){[(1R)-4-methylcyclohex-3-en-1-yl]carbonyl}-amino]thiophene-2-carboxylic acid monohydrate (Compound I Form VIII), characterized by an X-ray powder diffractogram comprising at least three of the following peaks:
- 3.8, 7.7, 7.9, 18.0, or 21.7 °
2θ
±
0.2 °
2θ
, as determined on a diffractometer using Cu-Kα
radiation.
2 Assignments
0 Petitions
Accused Products
Abstract
Crystalline solid forms and the amorphous form of the anti-HCV compound 5-(3,3-dimethylbutyn-1-yl)-3-[(cis-4-hydroxy-4-{[(3S)-tetrahydrofuran-3-yloxy]methyl}cyclohexyl){[(1R)-4-methylcyclohex-3-en-1-yl]carbonyl}amino]thiophene-2-carboxylic acid (Compound I) were prepared and characterized in the solid state:
Also provided are processes of manufacture and methods of using the crystalline forms.
-
Citations
24 Claims
-
1. Crystalline 5-(3,3-dimethylbutyn-1-yl)-3-[(cis-4-hydroxy-4-{[(3S)-tetrahydrofuran-3-yloxy]methyl}cyclohexyl){[(1R)-4-methylcyclohex-3-en-1-yl]carbonyl}-amino]thiophene-2-carboxylic acid monohydrate (Compound I Form VIII), characterized by an X-ray powder diffractogram comprising at least three of the following peaks:
- 3.8, 7.7, 7.9, 18.0, or 21.7 °
2θ
±
0.2 °
2θ
, as determined on a diffractometer using Cu-Kα
radiation. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)
- 3.8, 7.7, 7.9, 18.0, or 21.7 °
-
14. Crystalline 5-(3,3-dimethylbutyn-1-yl)-3-[(cis-4-hydroxy-4-{[(3S)-tetrahydrofuran-3-yloxy]methyl}cyclohexyl){[(1R)-4-methylcyclohex-3-en-1-yl]carbonyl}-amino]thiophene-2-carboxylic acid (Compound I Form XI), characterized by an X-ray powder diffractogram comprising at least three of the following peaks:
- 5.4, 5.7, 7.0, 7.9, or 8.6 °
2θ
±
0.2 °
2θ
, as determined on a diffractometer using Cu-Kα
. - View Dependent Claims (15, 16, 17, 18, 19, 20, 21, 22, 23, 24)
- 5.4, 5.7, 7.0, 7.9, or 8.6 °
Specification